Investigator(s):
Sherwin Isenberg, MD
Nov. 15 Event to Honor Outstanding Physician-Researchers
In a continuation of a tradition for recognizing its most outstanding physician-researchers, LA BioMed will celebrate the many accomplishments of Drs. Sherwin J. Isenberg, Nora C.J. Sun and Ronald S. Swerdloff on Nov. 15 at Legends 2016 at the Torrance Marriott Redondo Beach.
Investigator(s):
Richard Casaburi, PhD, MD
Study addresses long-standing question for those with moderately low blood oxygen levels
Newly published data from the Long-Term Oxygen Treatment Trial (LOTT) show that oxygen use is not beneficial for most people with chronic obstructive pulmonary disease (COPD) and moderately low levels of blood oxygen.
Investigator(s):
Eli Ipp, MD
Researchers find Divergent Views on Barriers to Diabetic Retinopathy Screening
LOS ANGELES – (Oct. 10, 2016) – While diabetes is the most common cause of blindness in the working-age population in the U.S., only about 55% of lower income adults living with the disease undergo the retinal screening needed to detect and help prevent blindness.
Investigator(s):
The Lundquist Institute
Funding to Help Create Incubator on Institute’s Campus to Help New Businesses Thrive
LOS ANGELES – (Oct. 4, 2016) – The Los Angeles County Board of Supervisors unanimously approved $3 million in funding today to help pay for the creation of a biosciences incubator on LA BioMed’s campus that will provide technical support and business services to help researchers bring promising new discoveries to market so the public can benefit from them.
Investigator(s):
The Lundquist Institute
Alliances to Strengthen Los Angeles County’s Life Sciences Community
California Life Sciences Association (CLSA), the nation’s largest statewide public policy and business leadership organization representing California’s leading life sciences innovators, today announced new strategic partnerships with LA BioMed and Lab Launch, and the unveiling of its Los Angeles satellite office, to regularly engage and bolster Los Angeles County’s life sciences community.
Dr. Joaquín Madrenas Brings Decades of Research Experience to the Institute
Further strengthening its research enterprise, LA BioMed announced today the addition of a new chief scientific officer to its leadership team, Joaquín (Quim) Madrenas, MD, PhD. Dr. Madrenas brings decades of experience as a researcher, physician, educator and administrator to one of the nation’s leading nonprofit independent research institutes.
Investigator(s):
Dong Chang, MD
New Study of Four Common Conditions Finds ICU Use Didn’t Improve Mortality Rates
LOS ANGELES – With the use of intensive care units (ICUs) on the rise in many hospitals, researchers at LA BioMed and UCLA examined ICU usage and found patients who were admitted to these units underwent more costly and invasive procedures but didn’t have better mortality rates than hospitalized patients with the same medical conditions who weren’t admitted to the ICU.
Investigator(s):
Jenny Shen, MD
New Study Finds ARB and ACEI Linked to Similar Results
LOS ANGELES – With cardiovascular disease being the No. 1 cause of death in end-stage kidney disease patients on peritoneal dialysis, a new study examined two classes of medications commonly prescribed to prevent cardiovascular events in these patients and found no significant difference in outcomes.
Creative Medical Technologies Licenses Patient-Specific Adult Stem Cell Therapy for Male Infertility
Investigator(s):
The Lundquist Institute
Clinical Stage Adult Stem Cell Company Expands Portfolio of Clinical Indications
Creative Medical Technologies, Inc. (CMT) announced today the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application # 14/508763, covering the use of stem cells for treatment of male infertility. In the patent application and a subsequent publication,[1] Ronald S.
Investigator(s):
Jenny Shen, MD
New Study Finds a 16% Reduction in Cardiovascular Events with the Use of ACEIs and ARBs
Two classes of blood pressure medications, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16% lower risk of strokes, heart attacks and death in patients with end-stage renal disease who are undergoing peritoneal dialysis, a new study in the journal, Nephrology Dialysis Transplantation, reports.